<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57112">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02028533</url>
  </required_header>
  <id_info>
    <org_study_id>UCSF-COOOL1</org_study_id>
    <nct_id>NCT02028533</nct_id>
  </id_info>
  <brief_title>Cocaine Opioid Oxytocin Option - Limited</brief_title>
  <acronym>COOOL</acronym>
  <official_title>Tolerability and Feasibility Study of Chronic Intranasal Oxytocin as an Adjunct to Methadone Maintenance Treatment in Patients With Co-occuring Opioid Use Disorder and Cocaine Use: A Two Week Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a pilot feasibility study assessing the tolerability of chronic administration
      of intranasal oxytocin to patients receiving methadone at an opioid replacement clinic who
      are actively using cocaine.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Number of patients with non-serious and serious adverse events</measure>
    <time_frame>3 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Opioid Use Disorder</condition>
  <condition>Cocaine Use Disorder</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intranasal oxytocin 40 International Units (IU) twice daily for two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <arm_group_label>Oxytocin</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enrolled as a patient in the San Francisco General Hospital Opioid Treatment
             Outpatient Program

          -  Stable dose of methadone for at least the past two weeks

          -  At least one routine urine toxicology screen positive for cocaine in the past month

        Exclusion Criteria:

          -  Positive urine pregnancy test

          -  Use of illicit drugs in the past month (with the exception of cocaine)

          -  Currently meets Diagnostic and Statistical Manual-5 (DSM-V) criteria for severe major
             depressive disorder with suicidal thoughts or actions

          -  History of psychotic or moderate-severe alcohol use disorder as defined by DSM-V
             criteria

          -  Severe neuropsychological disorder, brain trauma, epilepsy

          -  Sensitivity to preservatives (in particular E 216, E 218 and chlorobutanol
             hemihydrate)

          -  Nasal obstruction, discharge, or bleeding

          -  Habitually drinks large volumes of water

          -  Taking antipsychotics or mood stabilizers, testosterone or estrogen/progesterone
             supplement, or serotonin-1a receptor agonists/antagonists
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher S Stauffer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joshua Woolley, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher S Stauffer, MD</last_name>
    <phone>415-476-7247</phone>
    <email>christopher.stauffer@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivia Lam</last_name>
    <phone>415-221-4810</phone>
    <phone_ext>4117</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>San Francisco General Hospital Opiate Treatment Outpatient Program</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 3, 2014</lastchanged_date>
  <firstreceived_date>January 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Christopher Stauffer</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>addiction</keyword>
  <keyword>oxytocin</keyword>
  <keyword>tolerability</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
